Year: 2024

LG Sets New Standard in Accuracy and Reliability for In-Cabin Solutions with Ambarella-Powered Driver Monitoring System; Plans Demo During CES 2025 SEOUL, Korea and SANTA CLARA, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) — LG Electronics (LG), a mobility sector technology leader, and Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced that LG will showcase its latest in-cabin solution, developed in partnership with Ambarella, during CES 2025. Ambarella worked in close cooperation with LG to integrate its CV25 AI system-on-chip (SoC) into LG’s Driver Monitoring System (DMS), which allows automotive OEMs to deliver safer vehicles. This DMS is already in production with a global automotive OEM.With its industry-leading AI performance per watt, Ambarella’s CV25 chipset enables LG’s DMS to perform real time...

Approval of All Resolutions, Including Announced Transaction With Charme Capital Partners CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) — Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Extraordinary General Meeting. Shareholders voted in favor of all proposals, which included the approval of the previously announced envisaged sale and transfer of Centogene GmbH to Charme Capital Partners Limited, a pan-European private equity firm. At the Extraordinary General Meeting of CENTOGENE, 57.16% of the Company’s issued share capital were represented. About CENTOGENE CENTOGENE’s mission is to provide data-driven, life-changing answers to patients,...

Additional Funding for Next Phase of Heating at RF XL Commercial-Scale Pilot CALGARY, Alberta, Dec. 04, 2024 (GLOBE NEWSWIRE) — Acceleware Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of transformative technologies targeting the decarbonization of industrial process heat, is very pleased to announce an agreement for up to $1.31 million in non-dilutive grant funding with the Clean Resource Innovation Network (“CRIN”). The funding will be applied to eligible costs for the redeployment of upgraded subsurface components and the next phase of heating at the Marwayne, Alberta RF XL pilot (the “Project”). Eligible costs are incurred between January 1, 2024 and September 30, 2025. CRIN’s funding is intended to accelerate clean technology development and commercialization for oil and gas industry challenges, and...

CALGARY, Alberta, Dec. 04, 2024 (GLOBE NEWSWIRE) — Prospera Energy Inc. (TSX.V: PEI,) (“Prospera“, “PEI” or the “Corporation“) Prospera Energy is pleased to announce the completion and continuation of production optimization activities in its heavy oil properties, with both immediate increases in production and bolstering of field uptime and reliability. Five (5) wells have been successfully completed with the service rig out of an eight (8) well program, with a focus on pump changes, rod repairs, and tubing cleanouts. Additionally, two (2) of these wells have resulted in increased natural gas production, which is now used as fuel gas for the fields, significantly improving field reliability going forward. Furthermore, one high water-cut well was repaired, resulting in increased water production and enabling...

THE WOODLANDS, Texas, Dec. 04, 2024 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 531 homes in November 2024, including the bulk sale of 103 single-family rental homes. As of November 30, 2024, the Company had 142 active selling communities. About LGI Homes, Inc. Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. As one of America’s fastest growing companies, LGI Homes has closed over 70,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s...

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorexant) 25 and 50 mg was recently approved and is expected to launch in Japan in Q4 2024Tokyo, Japan and Cambridge, UK, 5 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces randomization of the first patient in a Phase 3 clinical trial evaluating daridorexant, its novel dual orexin receptor antagonist, for the treatment of adult patients in South Korea with insomnia. Insomnia, characterized by difficulties in sleep onset and/or sleep maintenance, impacts both physical and mental health. The condition is highly prevalent in South Korea, affecting 15-25% of the adult population, or approximately...

Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States Food and Drug Administration (FDA) has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy Revascor® (rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) designation following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life threatening congenital heart condition. Mesoblast Chief Executive Silviu Itescu said: “We appreciate FDA’s support...